US Food and Drug Administration revised EUA for sotrovimab due to Omicron BA.2 subvariant
On Mar. 25, 2022, GlaxoSmithKline and Vir Biotechnology announced that the US Food and Drug Administration had amended…
USDA confirmed highly pathogenic Avian influenza in Minnesota
On Mar. 25, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
Moderna finalized strategic partnership with Australian government
On Mar. 23, 2022, Moderna announced the finalization of a strategic partnership with the Australian Federal Government to…
Moderna announced COVID-19 vaccine phase 2/3 study in children 6 months to Under 6 years met Its primary endpoint
On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna…
Pfizer supplied UNICEF 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-Income countries
On Mar. 22, 2022, Pfizer announced an agreement with UNICEF to supply up to 4 million treatment courses…
Moderna announced new supply agreement for 2023 with Switzerland for seven million doses of COVID-19 booster vaccine
On Mar. 21, 2022, Moderna announced announced a supply agreement with the Swiss Federal Government for seven million…
Twist Bioscience launched synthetic RNA positive controls for SARS-CoV-2 encapsulated in imagene’s stainless steel capsules
On Mar. 21, 2022, Twist Bioscience announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated…
Researchers generated the first complete, gapless sequence of a human genome
On Mar. 21, 2022, in support of the Cancer Moonshot goal of fostering data sharing in cancer research,…
The Priestley Medal was awarded to Peter B. Dervan
On Mar. 20, 2022, the American Chemical Society awarded The Priestley Medal to Peter B. Dervan “to recognize…
Johnson & Johnson announced acquisition of Tibotec-Virco NV for $320 million in cash and debt
On Mar. 18, 2002, Johnson & Johnson announced an agreement to acquire all of the assets of Tibotec-Virco…
Biotechnology | Infectious Disease | Polio | Vaccine | WHO
More than 80 million doses administered to southern African children targeted in mass polio vaccination drives
On Mar. 18, 2022, the World Health Organization (WHO) announced that Malawi had launched the first round of…
Health Canada authorized Moderna’s COVID-19 vaccine in children (6-11 Years)
On Mar. 17, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
Soligenix COVID-19 vaccine, CiVax, boosted neutralizing activity against SARS-CoV-2, including Delta and Omicron
On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax (heat stable COVID-19…
USDA confirmed highly pathogenic Avian influenza in non-commercial backyard flock (Non-Poultry) in New Hampshire
On Mar. 17, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service confirmed (APHIS)…
Moderna submited amendment to EUA for an additional booster dose of its COVID-19 vaccine in the U.S.
On Mar. 17, 2022, Moderna announced that it had submitted a request to the U.S. Food and Drug…
Moderna to supply Japan with additional 70 million doses of COVID-19 booster vaccine
On Mar. 16, 2022, Moderna announced an agreement with the Ministry of Health, Labour and Welfare of Japan…
USDA confirmed highly pathogenic Avian influenza non-commercial backyard fock in Nebraska
On Mar. 16, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
Pfizer and BioNTech submitted for U.S. EUA of additional booster dose of COVID-19 vaccine for older adults
On Mar. 15, 2022, Pfizer and BioNTech announced the companies had submitted an application to the U.S. Food…
USDA confirmed highly pathogenic Avian influenza in Wisconsin
On Mar. 14, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection (APHIS) Service confirmed…
Moderna announced first participant dosed in phase 2 study of Omicron-specific bivalent booster candidate
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
USDA confirmed highly pathogenic Avian influenza in Kansas and Illinois
On Mar. 10, 2022, the Illinois Department of Agriculture (IDOA), in conjunction with the Illinois Department of Natural…
Cocrystal Pharma initiated enrollment in phase 1 influenza a study with novel, broad-spectrum, orally administrated antiviral CC-42344
On Mar. 10, 2022, Cocrystal Pharma announced dosing of the first subjects in a Phase 1 clinical trial…
Mandatory masking in schools reduced COVID-19 cases during Delta surge
On Mar. 10, 2022, schools with mandatory masking during the Delta surge had approximately 72% fewer cases of…
City of Hope COVID-19 vaccine showed effectiveness in phase 1 trial
On Mar. 10, 2022, the City of Hope announced that its COVID-19 investigational vaccine licensed to GeoVax Labs…
Pfizer initiated phase 2/3 study of novel COVID-19 oral treatment in pediatric participants
On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of ProteaseInhibition…
Moderna announced MOU with Government of Kenya to establish first mRNA manufacturing facility on the continent of Africa
On Mar. 7, 2022, Moderna announced that with the assistance of the U.S. Government, it had entered into…
USDA confirmed highlypathogenic Avian influenza in flock of commercial broiler chickens in Missouri
On Mar. 4, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
Agriculture | Biotechnology | Diagnostics | Disease | Infectious Disease | Influenza | Therapeutics | Vaccine
USDA confirmed highly pathogenic Avian influenza in two backyard flocks in Connecticut and Iowa
On Mar. 2, 2022, the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) confirmed the…
Biotechnology | COVID-19 | FDA | Therapeutics
Sorrento announced FDA authorization to proceed with phase 1 study of Intranasal STI-9199 against Covid-19 viruses
On Mar. 2, 2022, Sorrento Therapeutics announced that it had received clearance from the FDA for its investigational…
Sorrento announced COVISHIELD antibody nasal drops prevent productive SARS-CoV-2 infections
On Mar. 2, 2022, Sorrento Therapeutics announced that new preclinical results demonstrated that pretreating an animal with intranasal…